Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain chemistry experiment seeks clues in schizophrenia

NCT ID NCT04013555

Knowledge-focused Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how a supplement called N-acetylcysteine (NAC) affects brain chemicals and thinking in 88 adults with schizophrenia or related disorders. Participants took tryptophan to raise a brain chemical called kynurenic acid, then had cognitive tests and brain scans. The goal was to see if NAC could block certain brain changes and improve memory.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

88 people

The number who actually took part.

Started

Jan 2020

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females * Age: 18 to 55 years * DSM-5 Criteria for schizophrenia, schizoaffective disorder or schizophreniform disorder (documented by SCID) * Prescription of antipsychotic medication for at least 60 days and constant dose for 30 days prior to study entry (either first or second generation antipsychotics permitted) * Female participants must agree to use a medically accepted means of contraception Exclusion Criteria: * DSM-5 alcohol or substance misuse disorder in the last 3 months (documented by SCID) * History of an organic brain disorder; mental retardation; or a medical condition, whose pathology or treatment could alter cognition * Active disorders that have been reported to affect tryptophan metabolism or interfere with absorption will be excluded (Acute Intermittent Porphyria, Celiac Disease, Crohn's Disease, Irritable Bowel Syndrome; Brune and Pflughaupt 1975; Torres et al 2007). * Excessive self-reported daily caffeine intake, defined as intake exceeding 1000mg or the equivalent of 8 cups of coffee * Pregnancy or lactation * No metal in body that will interfere with MR imaging * Monoamine oxidase inhibitors, migraine headache medications (triptans) and dextromethorphan * Forensic or legal issues

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizoaffective disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Psychotic Disorders schizoaffective disorder schizophrenia schizophreniform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schizoaffective disorder Schizophrenia Schizophreniform disorder

Contacts and locations

Locations

  • Maryland Psychiatric Research Center (MPRC) ; the Treatment Research Program (TRP)

    Catonsville, Maryland, 21228, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.